• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.

作者信息

Keskin Ali Umit, Bolukcu Sibel, Ciragil Pinar, Topkaya Aynur Eren

机构信息

Department of Biomedical Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey.

Department of Infectious Diseases, Yeditepe University Kozyatagi Hospital, Istanbul, Turkey.

出版信息

J Med Virol. 2022 Jan;94(1):39-41. doi: 10.1002/jmv.27350. Epub 2021 Sep 21.

DOI:10.1002/jmv.27350
PMID:34536028
Abstract
摘要

相似文献

1
SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.两剂科兴疫苗接种方案后接种第三剂科兴疫苗或BNT162b2疫苗后的新冠病毒特异性抗体反应。
J Med Virol. 2022 Jan;94(1):39-41. doi: 10.1002/jmv.27350. Epub 2021 Sep 21.
2
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
3
Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.两剂科兴疫苗后是否应安排第三剂加强针？一项单中心经验。
J Med Virol. 2022 Jan;94(1):287-290. doi: 10.1002/jmv.27318. Epub 2021 Sep 10.
4
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.接种灭活疫苗后 160 天内血清抗 SARS-CoV-2 抗体的反应和持续时间。
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
5
Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers.接种两剂灭活全病毒疫苗、异源 mRNA-1273 疫苗加强针后，以及在印度尼西亚卫生保健工作者中发生奥密克戎突破性感染后抗 SARS-CoV-2 抗体的动态变化。
BMC Infect Dis. 2024 Aug 1;24(1):768. doi: 10.1186/s12879-024-09644-y.
6
A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.接种两剂新型冠状病毒灭活疫苗后，可能需要接种第三剂加强针以减轻中和抗体的衰减。
J Med Virol. 2022 Jan;94(1):35-38. doi: 10.1002/jmv.27334. Epub 2021 Sep 22.
7
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
8
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.接种 BBIBP-CorV 作为基础免疫后加强接种异源 Ad26.COV2.S 对 SARS-CoV-2 感染的效果：一项 1 年随访的 1/2 期开放标签试验。
Vaccine. 2024 Jul 25;42(19):3999-4010. doi: 10.1016/j.vaccine.2024.05.010. Epub 2024 May 13.
9
The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.新型冠状病毒（SARS-CoV-2）疫苗的黏膜和血清免疫应答。
Front Immunol. 2021 Oct 12;12:744887. doi: 10.3389/fimmu.2021.744887. eCollection 2021.
10
Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.医护人员接种两剂灭活病毒疫苗后的免疫原性：有和无既往 COVID-19 感染的前瞻性观察研究。
J Med Virol. 2022 Jan;94(1):279-286. doi: 10.1002/jmv.27316. Epub 2021 Sep 10.

引用本文的文献

1
Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.比较吸入式Ad5-nCoV疫苗异源加强针与混合免疫对奥密克戎BA.5感染的保护作用：一项针对中国医院工作人员的队列研究。
BMC Infect Dis. 2024 Dec 18;24(1):1401. doi: 10.1186/s12879-024-10250-1.
2
Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.异源和同源 COVID-19 加强疫苗接种的抗体反应比较：一项观察性研究。
Front Immunol. 2024 Nov 13;15:1448408. doi: 10.3389/fimmu.2024.1448408. eCollection 2024.
3
Clinical characteristics of COVID-19 clusters in three schools in Beijing, China: A retrospective study.
中国北京三所学校新冠病毒肺炎聚集性疫情的临床特征：一项回顾性研究
Heliyon. 2024 Jul 30;10(15):e35425. doi: 10.1016/j.heliyon.2024.e35425. eCollection 2024 Aug 15.
4
Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.泰国异源 COVID-19 疫苗方案有效性的持久性：使用国家登记数据的回顾性队列研究。
JMIR Public Health Surveill. 2024 Mar 5;10:e48255. doi: 10.2196/48255.
5
Antibody Response to COVID-19 Vaccines in Healthcare Workers: Which One is More Successful? Homologous or Heterologous?医护人员对新冠疫苗的抗体反应：哪种更有效？同源接种还是异源接种？
Sisli Etfal Hastan Tip Bul. 2023 Jun 20;57(2):216-223. doi: 10.14744/SEMB.2023.48264. eCollection 2023.
6
Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers.医护人员接种科兴疫苗和BNT162b2疫苗后抗体反应的比较。
Indian J Microbiol. 2023 Sep;63(3):361-368. doi: 10.1007/s12088-023-01098-1. Epub 2023 Sep 4.
7
Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia.印度尼西亚东爪哇省泗水市 COVID-19 疫苗接种人群中 SARS-CoV-2 刺突 IgG 抗体的血清阳性率。
PeerJ. 2023 Sep 25;11:e16142. doi: 10.7717/peerj.16142. eCollection 2023.
8
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study.土耳其针对严重急性呼吸综合征冠状病毒2的加强疫苗接种免疫原性的长期结果（混合COV-RAPEL TR研究）：一项双盲、随机、对照、多中心2期临床研究。
Vaccines (Basel). 2023 Jul 12;11(7):1234. doi: 10.3390/vaccines11071234.
9
Impact of Health Workers' Choice of COVID-19 Vaccine Booster on Immunization Levels in Istanbul, Turkey.土耳其伊斯坦布尔卫生工作者对新冠疫苗加强针的选择对免疫水平的影响
Vaccines (Basel). 2023 May 3;11(5):935. doi: 10.3390/vaccines11050935.
10
Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds.比较不同免疫背景下 COVID-19 疫苗的 T 细胞和 B 细胞反应。
Signal Transduct Target Ther. 2023 May 4;8(1):179. doi: 10.1038/s41392-023-01422-7.